Cancer cases are rising globally due to changes in the living lifestyle of the people. It is one of the major health concerns globally. According to GLOBOCAN, the number of new cancer cases is estimated to reach 24,044,406 in 2030 from 19,292,789 in 2020. To tackle this, extensive research studies help to gain knowledge about the biological processes involved in the body's onset, growth and spread of cancer. The study data and analysis of the results help prevent, diagnose, diagnose, and treat cancer at earlier stages. These ongoing research studies are aimed at advancing earlier discoveries and observations. Cell culture plays an important role in the basic cancer research for growing the cancer cells in different culture environments and in the presence of various chemicals to study their effect on cancerous cells.
Moreover, funding to support these research studies positively impacts the market. For instance, the National Cancer Institute (NCI) (U.S.) invests in a broad cancer research portfolio, from basic science to survivorship. According to their Annual Plan & Budget Proposal for Fiscal Year 2023 report, it is proposed that the NCI Research Project Grants will increase from USD 3.1 billion in 2022 to USD 4.2 billion by 2025.
Similarly, stem cells and cell lines are being used for the functional restoration of damaged tissues using tissue engineering and stem cell research. The ability of indefinite self-renewal and the potential to differentiate into any cell type makes stem cells most suitable for research. At present, donated tissues and organs cannot meet the transplantation demands of the diseased population because of the inability to differentiate into any cell type. Thus, animal cell culture is emerging as a new opportunity to repair tissue and organ anomalies due to congenital defects, disease, and age-associated effects. It was found that embryonic stem cells (ESC) can give rise to 200 types of cells and promise the treatment of any disease. This is because of the presence of pluripotency factors in the cells.
In the case of cardiovascular diseases, biomedical therapeutics help immediately restore heart functions. The regeneration of cardiac tissue can achieve this through ESCs-derived cardiovascular progenitors and bone marrow-derived mononuclear cells (BMDMNCs). Other stem cells, such as mesenchymal, umbilical cord, induced pluripotent, and bone marrow, are also used in regenerative medicine. In the past few decades, regenerative medicines have emerged in China and other countries like the U.S., Europe, Japan, and Singapore. Thus, stem cells can be used in regenerative medicine with their unique property of regeneration and self-renewal during structural or functional injury, thereby expanding stem cell research activities.
Additionally, the availability of funding to support stem cell research studies will further lead to increased demand for cell culture products. For instance, The Morrison Government boosted stem cell research in Australia by providing grants of USD 25 million, which will be available over five years from 2021–22, through two funding streams. In stream 1, up to USD 15 million will be used to support the development of novel stem-cell-based treatments. In stream 2, up to USD 10 million will be used to support large-scale projects focusing on pre-clinical evaluation and screening of new treatments. The research will use human tissues from stem cells involving large-scale multi-disciplinary teams.
Thus, ongoing cancer and stem cell research initiatives are expected to drive the global cell culture reagents market at a CAGR of 12.8% to reach $11.04 billion by 2029, according to Meticulous Research®.
Access Full Report Here: https://www.meticulousresearch.com/download-sample-report/cp_id=5322